Opiant Pharmaceuticals, Inc. (OPNT) |
|
11.95 -0.04 (-0.33%)
|
07-02 16:00 |
|
Open: |
11.97 |
Pre. Close: |
11.99 |
|
High:
|
12.4889 |
Low:
|
11.5 |
|
Volume:
|
11,104 |
Market Cap:
|
61(M) |
|
|
|
|
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
12.49 - 12.58 |
12.58 - 12.65 |
|
Low:
|
11.35 - 11.43 |
11.43 - 11.49 |
|
Close:
|
11.83 - 11.96 |
11.96 - 12.07 |
|
Technical analysis |
as of: 2022-07-01 4:24:12 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 15.5 One year: 17.5 |
| Support: |
Support1: 10.48 Support2: 8.72 |
| Resistance: |
Resistance1: 13.27 Resistance2: 14.98 |
| Pivot: |
11.57  |
| Moving Average: |
MA(5): 11.95 MA(20): 11.74
MA(100): 19.31 MA(250): 22.16 |
| MACD: |
MACD(12,26): -0.7 Signal(9): -1 |
| Stochastic oscillator: |
%K(14,3): 57.2 %D(3): 56.8 |
| RSI: |
RSI(14): 44.5 |
| 52-week: |
High: 37.7 Low: 7.34 |
| Average Vol(K): |
3-Month: 90 (K) 10-Days: 22 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ OPNT ] has closed below upper band by 33.7%. Bollinger Bands are 63.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Tue, 28 Jun 2022
2022-06-28 | NDAQ:OPNT | Press Release | Opiant Pharmaceuticals Inc. - Stockhouse
Mon, 13 Jun 2022
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Director Craig A. Collard Acquires 1663 Shares - Defense World
Thu, 09 Jun 2022
Health Care Sector Update for 06/09/2022: SONN, OPNT, CVAC, XLV, IBB - Nasdaq
Wed, 08 Jun 2022
Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene - Yahoo Finance
Wed, 08 Jun 2022
Michael Sinclair Sells 7688 Shares of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Stock - Defense World
Mon, 06 Jun 2022
Small Cap Psychedelic Play Vying for Future Leadership in Addiction Treatment (AXSM, AWKNF, BICX, OPNT, ALKS, PFE, AMPH, OMER) - BP Journal
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
5 (M) |
| Shares Float |
5 (M) |
|
% Held by Insiders
|
6.8 (%) |
|
% Held by Institutions
|
34 (%) |
|
Shares Short
|
66 (K) |
|
Shares Short P.Month
|
29 (K) |
Stock Financials |
|
EPS
|
0.31 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0.5 |
|
EPS Est Next Year
|
1.25 |
|
Book Value (p.s.)
|
9.1 |
|
Profit Margin (%)
|
6.3 |
|
Operating Margin (%)
|
10.7 |
|
Return on Assets (ttm)
|
4.9 |
|
Return on Equity (ttm)
|
7.3 |
|
Qtrly Rev. Growth
|
39 |
|
Gross Profit (p.s.)
|
4.63 |
|
Sales Per Share
|
10.12 |
|
EBITDA (p.s.)
|
1.11 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
2 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
38.54 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.31 |
|
Price to Sales
|
1.18 |
|
Price to Cash Flow
|
29.22 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
